2seventy bio, Inc. (TSVT) Financial Analysis & Valuation | Quarter Chart
2seventy bio, Inc. (TSVT)
TSVTPrice: $5
Fair Value: 🔒
🔒score
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of... more
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and comme... more
Description
Shares
| Market Cap | $266.14M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | William D. Baird III, |
| IPO Date | 2021-11-03 | CAGR | -0.06% |
| Employees | 65 | Website | www.2seventybio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
TSVT chart loading...
Fundamentals
Technicals
| Enterprise Value | $409.50M | P/E Ratio | -62.5 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 5.5 | P/B Ratio | 1.24 |
| P/CF Ratio | -4.9 | P/FCF Ratio | -4.91 |
| EPS | $-0.08 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -32.07% | Gross Margin | 0.56% |
| Operating Margin | -1.24% | Profit Margin | -0.08% |
| ROE | -0.02% | ROA | -0.01% |
| ROCE | -0.14% | Current Ratio | 4.8 |
| Quick Ratio | 4.8 | Cash Ratio | 2.23 |
| Debt/Equity | 1.12 | Interest Coverage | — |
| Altman Z Score | -0.97 | Piotroski Score | 2 |